Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CST-2032 and CST-107 in MCI or Mild Dementia due to AD or PD
NCT05104463Phase 2Completed
- Sponsor
- CuraSen Therapeutics
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of CST-2032 in Alzheimer's disease (AD), Parkinson's disease (PD), Mild Cognitive Impairment (MCI), Dementia, sponsored by CuraSen Therapeutics. Started Apr 2022; status: completed.
02
Drugs
CST-2032
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)Mild Cognitive Impairment (MCI)Dementia
Beyond the preview
Go deeper on NCT05104463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104463.